

Harrison W Farber

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2537071/harrison-w-farber-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

180
papers

10,423
citations

47
h-index

100
g-index

192
ext. papers

11,818
ext. citations

5.9
avg, IF

5.88
L-index

#	Paper	IF	Citations
180	Pulmonary Arterial Hypertension in Patients Infected with the Human Immunodeficiency Virus. <i>Cardiology Clinics</i> , 2022 , 40, 45-54	2.5	1
179	Application of the REVEAL risk score calculator 2.0 in the CHEST study.. <i>Respiratory Medicine</i> , 2022 , 195, 106783	4.6	
178	Risk assessment in patients with pulmonary arterial hypertension in the era of COVID 19 pandemic and the telehealth revolution: State of the art review. <i>Journal of Heart and Lung Transplantation</i> , 2021 , 40, 172-182	5.8	2
177	Patient and disease characteristics of the first 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERE. <i>Journal of Heart and Lung Transplantation</i> , 2021 , 40, 279-288	5.8	3
176	A Pilot Study of Dimethyl Fumarate in Pulmonary Arterial Hypertension Associated with Systemic Sclerosis.. <i>Journal of Scleroderma and Related Disorders</i> , 2021 , 6, 242-246	2.3	1
175	Rare variant analysis of 4241 pulmonary arterial hypertension cases from an international consortium implicates FBLN2, PDGFD, and rare de novo variants in PAH. <i>Genome Medicine</i> , 2021 , 13, 80	14.4	11
174	Treatment of pulmonary hypertension in patients with Hereditary Hemorrhagic Telangiectasia - A case series and systematic review. <i>Pulmonary Pharmacology and Therapeutics</i> , 2021 , 68, 102033	3.5	3
173	Pulmonary Tumor Thrombotic Microangiopathy as a Cause of Pulmonary Hypertension. <i>JACC: Case Reports</i> , 2021 , 3, 1029-1031	1.2	0
172	Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension. <i>Chest</i> , 2021 , 159, 337-346	5.3	29
171	United States Pulmonary Hypertension Scientific Registry: Baseline Characteristics. <i>Chest</i> , 2021 , 159, 311-327	5.3	7
170	Severe Digit Ischemia Associated with Scleroderma: a Case Report and Treatment Guide. <i>SN Comprehensive Clinical Medicine</i> , 2021 , 3, 306-308	2.7	
169	Pulmonary Hypertension in Chronic Kidney Disease. <i>Cardiology Clinics</i> , 2021 , 39, 427-434	2.5	3
168	Pulmonary vasculitis in Hughes-Stovin syndrome (HSS): a reference atlas and computed tomography pulmonary angiography guide-a report by the HSS International Study Group. <i>Clinical Rheumatology</i> , 2021 , 40, 4993-5008	3.9	2
167	Aggressive Afterload Lowering to Improve the RV: A New Target for Medical Therapy in PAH?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 ,	10.2	2
166	Prevalence and Mortality of Pulmonary Hypertension in ESRD: A Systematic Review and Meta-analysis. <i>Lung</i> , 2020 , 198, 535-545	2.9	6
165	Management of hospitalized patients with pulmonary arterial hypertension and COVID-19 infection. <i>Pulmonary Circulation</i> , 2020 , 10, 2045894020933480	2.7	5
164	Stress Cardiomyopathy Precipitated by Withdrawal of Epoprostenol. <i>JACC: Case Reports</i> , 2020 , 2, 289-293	2.2	1

163	Long-term outcomes of epoprostenol therapy in sarcoid associated pulmonary hypertension. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2020 , 37, 184-191	1.1	0
162	Treatment of newly diagnosed sarcoid-associated pulmonary hypertension with ambrisentan and tadalafil combination therapy. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2020 , 37, 234-238	1.1	
161	Pulmonary hypertension secondary to takayasu's arteritis: management using a combined medical and interventional approach. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2020 , 37, 239-241	1.1	
160	Unilateral Chronic Thromboembolic Pulmonary Disease: A Mimic of Pulmonary Artery Agenesi. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 201, e74-e75	10.2	
159	Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway Agents. <i>Chest</i> , 2020 , 157, 955-965	5.3	14
158	Novel composite clinical endpoints and risk scores used in clinical trials in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2020 , 10, 2045894020962960	2.7	4
157	Clinical trial design in phase 2 and 3 trials for pulmonary hypertension. <i>Pulmonary Circulation</i> , 2020 , 10, 2045894020941491	2.7	1
156	Swan-Ganz and Pericardial Pressure-guided Pericardiocentesis in Pulmonary Arterial Hypertension-associated Cardiac Tamponade. <i>Annals of the American Thoracic Society</i> , 2019 , 16, 1189-1197	4.7	1
155	The New World Symposium on Pulmonary Hypertension Guidelines: Should Twenty-One Be the New Twenty-Five?. <i>Circulation</i> , 2019 , 140, 1134-1136	16.7	5
154	Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019 , 12, e005095	5.8	5
153	United States Pulmonary Hypertension Scientific Registry (USPHSR): rationale, design, and clinical implications. <i>Pulmonary Circulation</i> , 2019 , 9, 2045894019851696	2.7	5
152	Barriers to frostbite treatment at an academic medical center. <i>American Journal of Emergency Medicine</i> , 2019 , 37, 1601.e3-1601.e5	2.9	5
151	Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies. <i>Chest</i> , 2019 , 156, 323-337	5.3	201
150	Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	32
149	Pharmacokinetics of ambrisentan in a patient with Pulmonary Arterial Hypertension and a total gastrectomy. <i>Pulmonary Pharmacology and Therapeutics</i> , 2019 , 57, 101813	3.5	
148	Thyroid Dysfunction in Patients with Pulmonary Artery Hypertension (PAH): The Effect of Therapies Affecting the Prostanoid Pathway. <i>Lung</i> , 2019 , 197, 761-768	2.9	6
147	Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial. <i>European Respiratory Journal</i> , 2019 , 54,	13.6	13
146	Use of ultrasound-measured internal jugular vein collapsibility index to determine static intracardiac pressures in patients with presumed pulmonary hypertension. <i>Annals of Intensive Care</i> , 2019 , 9, 124	8.9	3

145	PH Grand Rounds: A Case of Pulmonary Hypertension Associated With High Cardiac Output State from Arteriovenous Fistula Or Is It?. <i>Advances in Pulmonary Hypertension</i> , 2019 , 18, 70-73	0.5	
144	A Man with End-Stage Renal Disease, Dyspnea, and an Abnormal Echocardiogram. <i>Annals of the American Thoracic Society</i> , 2019 , 16, 1577-1581	4.7	
143	Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study. <i>Journal of Heart and Lung Transplantation</i> , 2019 , 38, 43-50	5.8	16
142	REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat. <i>Journal of Heart and Lung Transplantation</i> , 2018 , 37, 836-843	5.8	14
141	Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL Registry. <i>Chest</i> , 2018 , 154, 126-135	5.3	23
140	Pulmonary Cavity From in an HIV-Infected Patient: Complicated by Bronchopleural Fistula. <i>Open Forum Infectious Diseases</i> , 2018 , 5, ofy023	1	
139	Use of supplemental oxygen in patients with pulmonary arterial hypertension in REVEAL. <i>Journal of Heart and Lung Transplantation</i> , 2018 , 37, 948-955	5.8	7
138	Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study. <i>Journal of Heart and Lung Transplantation</i> , 2018 , 37, 401-408	5.8	12
137	Serum biomarker for diagnostic evaluation of pulmonary arterial hypertension in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2018 , 20, 185	5.7	9
136	REVEAL risk scores applied to riociguat-treated patients in PATENT-2: Impact of changes in risk score on survival. <i>Journal of Heart and Lung Transplantation</i> , 2018 , 37, 513-519	5.8	22
135	Impact of declining renal function on outcomes in pulmonary arterial hypertension: A REVEAL registry analysis. <i>Journal of Heart and Lung Transplantation</i> , 2018 , 37, 696-705	5.8	16
134	Response. <i>Chest</i> , 2018 , 154, 1262-1264	5.3	
133	Patients with systemic sclerosis-associated pulmonary arterial hypertension express a genomic signature distinct from patients with interstitial lung disease. <i>Journal of Scleroderma and Related Disorders</i> , 2018 , 3, 242-248	2.3	8
132	Changes in gene expression profiles in patients with pulmonary arterial hypertension associated with scleroderma treated with tadalafil. <i>Seminars in Arthritis and Rheumatism</i> , 2017 , 46, 465-472	5.3	6
131	A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis. <i>Genome Medicine</i> , 2017 , 9, 27	14.4	60
130	Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series. <i>Pulmonary Circulation</i> , 2017 , 7, 741-746 ²⁷	2.7	10
129	Clinical Assessment of Pulmonary Hypertension 2017 , 403-409		
128	Gaps and Controversies of New Treatment Recommendations in Recent Pulmonary Hypertension Guidelines: What We Know and What We Don't. <i>Advances in Pulmonary Hypertension</i> , 2017 , 16, 20-25	0.5	

127	Ranolazine for the treatment of pulmonary hypertension associated with heart failure with preserved ejection fraction: A pilot study. <i>Journal of Heart and Lung Transplantation</i> , 2016 , 35, 1370-1373	5.8	2
126	Pharmacokinetic drug evaluation of selexipag for the treatment of pulmonary arterial hypertension. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016 , 12, 1513-1520	5.5	5
125	Patient Registries in Pulmonary Arterial Hypertension: the Role of Survival Equations and Risk Calculators 2016 , 307-325		1
124	Anti-coagulation in pulmonary arterial hypertension: the real blood and guts. <i>Journal of Thoracic Disease</i> , 2016 , 8, E1106-E1107	2.6	2
123	Practical considerations for therapies targeting the prostacyclin pathway. <i>European Respiratory Review</i> , 2016 , 25, 418-430	9.8	22
122	Perspectives on oral pulmonary hypertension therapies recently approved by the U.S. Food and Drug Administration. <i>Annals of the American Thoracic Society</i> , 2015 , 12, 269-73	4.7	8
121	Pulmonary hypertension associated with heart failure with preserved ejection fraction: acute hemodynamic effects of inhaled iloprost. <i>Pulmonary Circulation</i> , 2015 , 5, 198-203	2.7	12
120	Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance. <i>Journal of Heart and Lung Transplantation</i> , 2015 , 34, 362-8	5.8	74
119	Validation of two predictive models for survival in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2015 , 46, 152-64	13.6	62
118	Novel investigational therapies for treating pulmonary arterial hypertension. <i>Expert Opinion on Investigational Drugs</i> , 2015 , 24, 1571-96	5.9	11
117	Hospitalization and survival in patients using epoprostenol for injection in the PROSPECT observational study. <i>Chest</i> , 2015 , 147, 484-494	5.3	27
116	Prevalence and hospital discharge status of human immunodeficiency virus-associated pulmonary arterial hypertension in the United States. <i>Pulmonary Circulation</i> , 2015 , 5, 506-12	2.7	9
115	Gestational pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2015 , 5, 730-3	2.7	5
114	The HLA-B*35 allele modulates ER stress, inflammation and proliferation in PBMCs from Limited Cutaneous Systemic Sclerosis patients. <i>Arthritis Research and Therapy</i> , 2015 , 17, 363	5.7	12
113	Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. <i>American Journal of Hematology</i> , 2015 , 90, 1060-4	7.1	83
112	Under pressure: pulmonary hypertension associated with left heart disease. <i>European Respiratory Review</i> , 2015 , 24, 665-73	9.8	17
111	Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL). <i>Circulation</i> , 2015 , 132, 2403-11	16.7	97
110	Using Clinical Trial End Points to Risk Stratify Patients With Pulmonary Arterial Hypertension. <i>Circulation</i> , 2015 , 132, 2152-61	16.7	10

109	Relation of novel echocardiographic measures to invasive hemodynamic assessment in scleroderma-associated pulmonary arterial hypertension. <i>Arthritis Care and Research</i> , 2014 , 66, 1386-94	4.7	15
108	Cause of death in patients with pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2014 , 33, 222	5.8	1
107	Pharmacokinetic evaluation of treprostinil (oral) for the treatment of pulmonary arterial hypertension. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014 , 10, 1445-53	5.5	4
106	Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. <i>Chest</i> , 2014 , 146, 1494-1504	5.3	94
105	Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL Registry. <i>Journal of Heart and Lung Transplantation</i> , 2013 , 32, 1114-22	5.8	74
104	Pulmonary hypertension associated with chronic hemolytic anemia and other blood disorders. <i>Clinics in Chest Medicine</i> , 2013 , 34, 739-52	5.3	30
103	Transcatheter Potts shunt creation in patients with severe pulmonary arterial hypertension: initial clinical experience. <i>Journal of Heart and Lung Transplantation</i> , 2013 , 32, 381-7	5.8	95
102	Demographics and outcomes of patients diagnosed with pulmonary hypertension with pulmonary capillary wedge pressures 16 to 18 mm Hg: insights from the REVEAL Registry. <i>Chest</i> , 2013 , 143, 185-195	5.3	46
101	Increased expression of endoplasmic reticulum stress and unfolded protein response genes in peripheral blood mononuclear cells from patients with limited cutaneous systemic sclerosis and pulmonary arterial hypertension. <i>Arthritis and Rheumatism</i> , 2013 , 65, 1357-66		49
100	Use of selective serotonin reuptake inhibitors and outcomes in pulmonary arterial hypertension. <i>Chest</i> , 2013 , 144, 531-541	5.3	33
99	Comorbid conditions and outcomes in patients with pulmonary arterial hypertension: a REVEAL registry analysis. <i>Chest</i> , 2013 , 144, 169-176	5.3	86
98	ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. <i>Cardiovascular Therapeutics</i> , 2012 , 30, 93-9	3.3	67
97	Clinical Assessment of Pulmonary Hypertension 2012 , 429-435		
96	Bloodstream infections in patients with pulmonary arterial hypertension treated with intravenous prostanoids: insights from the REVEAL REGISTRY. <i>Mayo Clinic Proceedings</i> , 2012 , 87, 825-34	6.4	50
95	Ophthalmologic diagnosis of exacerbation of idiopathic pulmonary arterial hypertension. <i>JAMA Ophthalmology</i> , 2012 , 130, 1619-21		5
94	Differential response to intravenous prostacyclin analog therapy in patients with pulmonary arterial hypertension. <i>Pulmonary Pharmacology and Therapeutics</i> , 2011 , 24, 421-5	3.5	8
93	Pulmonary hypertension: screening and evaluation in scleroderma. <i>Current Opinion in Rheumatology</i> , 2011 , 23, 536-44	5.3	14
92	The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. <i>Chest</i> , 2011 , 139, 128-37	5.3	231

91	Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry. <i>Chest</i> , 2011 , 140, 19-26	5.3	167
90	REVEAL Registry: correlation of right heart catheterization and echocardiography in patients with pulmonary arterial hypertension. <i>Congestive Heart Failure</i> , 2011 , 17, 56-64		71
89	Interferon and alternative activation of monocyte/macrophages in systemic sclerosis-associated pulmonary arterial hypertension. <i>Arthritis and Rheumatism</i> , 2011 , 63, 1718-28		97
88	Early pulmonary embolectomy for acute pulmonary embolus: an operation whose time has come. <i>Journal of Cardiac Surgery</i> , 2010 , 25, 259-60	1.3	4
87	The accuracy of the central venous blood gas for acid-base monitoring. <i>Journal of Intensive Care Medicine</i> , 2010 , 25, 104-10	3.3	40
86	Cardiopulmonary exercise testing with right-heart catheterization in patients with systemic sclerosis. <i>Journal of Rheumatology</i> , 2010 , 37, 1871-7	4.1	14
85	Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. <i>Chest</i> , 2010 , 137, 376-87	5.3	798
84	Care of patients with scleroderma in the intensive care setting. <i>Journal of Intensive Care Medicine</i> , 2010 , 25, 247-58	3.3	9
83	Pulmonary hypertension associated with left ventricular diastolic dysfunction. <i>Journal of Heart and Lung Transplantation</i> , 2010 , 29, 230-1	5.8	4
82	Ethical issues associated with globalization of placebo-controlled in pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2010 , 29, 825-6	5.8	5
81	The role of aldosterone in pulmonary venous hypertension. <i>Chest</i> , 2010 , 137, 502; author reply 502	5.3	
80	Successful bosentan and nonnucleoside reverse transcriptase inhibitor-based therapy in a patient with acquired immunodeficiency syndrome and pulmonary arterial hypertension. <i>Pharmacotherapy</i> , 2010 , 30, 139e-44e	5.8	6
79	Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury. <i>PLoS ONE</i> , 2010 , 5, e12106	3.7	101
78	ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. <i>Circulation</i> , 2009 , 120, 225-34	16.7	829
77	Adiponectin deficiency: a model of pulmonary hypertension associated with pulmonary vascular disease. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2009 , 297, L432-8	5.8	88
76	Effect of sodium butyrate on lung vascular TNFSF15 (TL1A) expression: differential expression patterns in pulmonary artery and microvascular endothelial cells. <i>Cytokine</i> , 2009 , 46, 72-8	4	9
75	Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review. <i>American Heart Journal</i> , 2009 , 157, 625-35	4.9	31
74	ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc., and the Pulmonary Hypertension Association. <i>Journal of the American College of Cardiology</i> , 2009 , 53, 1573-619	15.1	1257

73	On the importance of plasmalogen status in stimulated arachidonic acid release in the macrophage cell line RAW 264.7. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2008 , 1781, 213-9 ⁵		18
72	Design of the REVEAL registry for US patients with pulmonary arterial hypertension. <i>Mayo Clinic Proceedings</i> , 2008 , 83, 923-31	6.4	54
71	Propylene glycol accumulation during continuous-infusion lorazepam in critically ill patients. <i>Journal of Intensive Care Medicine</i> , 2008 , 23, 413; author reply 414-5	3.3	3
70	Design of the REVEAL Registry for US Patients With Pulmonary Arterial Hypertension. <i>Mayo Clinic Proceedings</i> , 2008 , 83, 923-931	6.4	104
69	Pulmonary arterial hypertension and left-sided heart disease in sickle cell disease: clinical characteristics and association with soluble adhesion molecule expression. <i>American Journal of Hematology</i> , 2008 , 83, 547-53	7.1	48
68	Connective Tissue Disease Associated Pulmonary Hypertension 2008 , 145-171		
67	Pathophysiology of Pulmonary Arterial Hypertension 2008 , 51-72		1
66	Identification of oxidative post-translational modification of serum albumin in patients with idiopathic pulmonary arterial hypertension and pulmonary hypertension of sickle cell anemia. <i>Rapid Communications in Mass Spectrometry</i> , 2007 , 21, 2195-203	2.2	24
65	Micrococcus bacteremia in a patient with pulmonary hypertension and a long-term central venous catheter: Opportunity knocks, and an unexpected pathogen enters. <i>Clinical Microbiology Newsletter</i> , 2007 , 29, 173-175	1.1	2
64	Pulmonary hypertension and beta-thalassemia major: report of a case, its treatment, and a review of the literature. <i>American Journal of Hematology</i> , 2006 , 81, 443-7	7.1	20
63	Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot study. <i>Chest</i> , 2006 , 130, 1471-80	5.3	36
62	Synthesis and biological properties of the fluorescent ether lipid precursor 1-O-[9S(1S ^{pyrenyl})]nonyl-sn-glycerol. <i>Journal of Lipid Research</i> , 2006 , 47, 633-42	6.3	9
61	Heart failure with preserved ejection fraction. <i>New England Journal of Medicine</i> , 2006 , 355, 1828; author reply 1830-1	59.2	1
60	Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. <i>Chest</i> , 2006 , 130, 1481-8	5.3	125
59	Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. <i>Annals of Internal Medicine</i> , 2006 , 145, 152-3	8	111
58	Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension. <i>Chest</i> , 2006 , 129, 417-425	5.3	79
57	Propylene glycol toxicity: a severe iatrogenic illness in ICU patients receiving IV benzodiazepines: a case series and prospective, observational pilot study. <i>Chest</i> , 2005 , 128, 1674-81	5.3	136
56	Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension. <i>Respiratory Medicine</i> , 2005 , 99, 1501-10	4.6	70

55	Acute cardiopulmonary hemodynamic effects of brain natriuretic peptide in patients with pulmonary arterial hypertension. <i>Chest</i> , 2005 , 128, 618S-619S	5.3	7
54	Sickle cell vaso-occlusive crisis induces the release of circulating serum heat shock protein-70. <i>American Journal of Hematology</i> , 2005 , 78, 240-2	7.1	36
53	Differential gene expression in pulmonary artery endothelial cells exposed to sickle cell plasma. <i>Physiological Genomics</i> , 2005 , 21, 293-8	3.6	17
52	Mechanism of disease: Pulmonary hypertension. <i>Discovery Medicine</i> , 2005 , 5, 80-7	2.5	1
51	Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. <i>New England Journal of Medicine</i> , 2004 , 350, 2521-2; author reply 2521-2	59.2	15
50	Pulmonary arterial hypertension. <i>New England Journal of Medicine</i> , 2004 , 351, 1655-65	59.2	982
49	A Sickle Transgenic Mouse Model of Acute Chest Syndrome.. <i>Blood</i> , 2004 , 104, 3585-3585	2.2	
48	Gabapentin toxicity requiring intubation in a patient receiving long-term hemodialysis. <i>Annals of Internal Medicine</i> , 2002 , 137, 74	8	25
47	Identification of protein disulfide isomerase as an endothelial hypoxic stress protein. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2002 , 282, L996-1003	5.8	33
46	Cellular glutathione peroxidase deficiency and endothelial dysfunction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2002 , 282, H1255-61	5.2	144
45	Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002 , 165, 341-4	10.2	119
44	Increasing plasminogen levels protects human endothelial cells during hypoxia. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2002 , 283, H671-9	5.2	65
43	Immune restoration syndrome manifested by pulmonary sarcoidosis. <i>American Journal of Roentgenology</i> , 2001 , 177, 1427	5.4	17
42	Current management of primary pulmonary hypertension. <i>Drugs</i> , 2001 , 61, 1945-56	12.1	27
41	Role of free radicals in the pathogenesis of acute chest syndrome in sickle cell disease. <i>Respiratory Research</i> , 2001 , 2, 280-5	7.3	93
40	Gas 6 promotes Axl-mediated survival in pulmonary endothelial cells. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2001 , 280, L1273-81	5.8	47
39	Induction of endothelial cell cytoplasmic lipid bodies during hypoxia. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2001 , 280, H294-301	5.2	25
38	IV epoprostenol for systemic sclerosis. <i>Chest</i> , 2000 , 118, 881-2	5.3	

37	VEGF is deposited in the subepithelial matrix at the leading edge of branching airways and stimulates neovascularization in the murine embryonic lung. <i>Developmental Dynamics</i> , 2000 , 219, 341-52 ^{2.9}	102
36	Induction of heme oxygenase-1 by hypoxia and free radicals in human dermal fibroblasts. <i>American Journal of Physiology - Cell Physiology</i> , 2000 , 278, C92-C101	5.4 87
35	Propylene glycol toxicity in a patient receiving intravenous diazepam. <i>New England Journal of Medicine</i> , 2000 , 343, 815	59.2 48
34	Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. <i>Journal of Clinical Investigation</i> , 2000 , 106, 483-91	15.9 316
33	Endothelial cell nitric oxide production in acute chest syndrome. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1999 , 277, H1579-92	5.2 24
32	Successful treatment of chylous ascites secondary to Mycobacterium avium complex in a patient with the acquired immune deficiency syndrome. <i>American Journal of Gastroenterology</i> , 1999 , 94, 1689-90 ^{0.7}	17
31	Identification of an oxygen responsive enhancer element in the glyceraldehyde-3-phosphate dehydrogenase gene. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1999 , 1447, 208-18	84
30	Prothrombotic mechanisms in primary pulmonary hypertension. <i>Translational Research</i> , 1999 , 134, 561-6	24
29	Systemic sclerosis-associated pulmonary hypertension: short- and long-term effects of epoprostenol (prostacyclin). <i>Arthritis and Rheumatism</i> , 1999 , 42, 2638-45	68
28	Endothelial cell hypoxic stress proteins. <i>Translational Research</i> , 1998 , 132, 456-63	46
27	Hypoxic regulation of endothelial glyceraldehyde-3-phosphate dehydrogenase. <i>American Journal of Physiology - Cell Physiology</i> , 1998 , 274, C347-55	5.4 77
26	Effect of hypercarbia on surface proteins of cultured bovine endothelial cells. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 1997 , 273, L1141-6	5.8 3
25	Endothelial hypoxic stress proteins. <i>Kidney International</i> , 1997 , 51, 426-37	9.9 14
24	Endotracheal reintubation: a closer look at a preventable condition. <i>Clinical Nurse Specialist</i> , 1997 , 11, 145-50; quiz 151-2	0.6 4
23	Non-neuronal enolase is an endothelial hypoxic stress protein. <i>Journal of Biological Chemistry</i> , 1995 , 270, 27752-7	5.4 118
22	Serotonin-stimulated aortic endothelial cells secrete a novel T lymphocyte chemotactic and growth factor. <i>Journal of Leukocyte Biology</i> , 1994 , 55, 567-73	6.5 20
21	Secretion of a novel T-lymphocyte cytokine possessing both chemotactic and growth factor activity by serotonin-stimulated human aortic endothelial cells. <i>Experimental Cell Research</i> , 1994 , 212, 113-9	4.2 3
20	The closed tracheal suction system: implications for critical care nursing. <i>Dimensions of Critical Care Nursing</i> , 1994 , 13, 292-300	1.9 12

19	Effect of hypoxia on endothelial cell surface glycoprotein expression: modulation of glycoprotein IIIa and other specific surface glycoproteins. <i>Experimental Cell Research</i> , 1993 , 208, 465-78	4.2	14
18	Endothelial cell hypoxia associated proteins are cell and stress specific. <i>Journal of Cellular Physiology</i> , 1993 , 157, 544-54	7	64
17	Nutritional outcome and pneumonia in critical care patients randomized to gastric versus jejunal tube feedings. The Critical Care Research Team. <i>Critical Care Medicine</i> , 1992 , 20, 1377-87	1.4	318
16	Production of neutrophil-specific lipid chemoattractant activity by cultured endothelial cells: heterogeneity dependent on species, ligand, or endothelial cell site of origin. <i>Tissue and Cell</i> , 1992 , 24, 355-66	2.7	1
15	Effect of an endurance triathlon on pulmonary function. <i>Medicine and Science in Sports and Exercise</i> , 1991 , 23, 1260-1264	1.2	26
14	The endurance triathlon. <i>Medicine and Science in Sports and Exercise</i> , 1991 , 23, 959-965	1.2	23
13	Atenolol-induced cardiovascular collapse treated with hemodialysis. <i>Critical Care Medicine</i> , 1991 , 19, 116-8	1.4	23
12	<i>Mycobacterium gordonae</i> : a possible opportunistic respiratory tract pathogen in patients with advanced human immunodeficiency virus, type 1 infection. <i>Chest</i> , 1991 , 100, 716-20	5.3	30
11	Effect of long-term hypoxia on cultured aortic and pulmonary arterial endothelial cells. <i>Experimental Cell Research</i> , 1990 , 191, 27-36	4.2	21
10	Acute changes in lipid, lipoprotein, apolipoprotein, and low-density lipoprotein particle size after an endurance triathlon. <i>Metabolism: Clinical and Experimental</i> , 1989 , 38, 921-5	12.7	57
9	Pulmonary response to foreign body microemboli in dogs: release of neutrophil chemoattractant activity by vascular endothelial cells. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1989 , 1, 27-35	5.7	13
8	Effects of hypoxia and hypercarbia on cultured endothelial cells. <i>Chest</i> , 1988 , 93, 156S-157S	5.3	
7	Nosocomial pneumonia in intubated patients given sucralfate as compared with antacids or histamine type 2 blockers. The role of gastric colonization. <i>New England Journal of Medicine</i> , 1987 , 317, 1376-82	59.2	665
6	Human pulmonary dirofilariasis infection. <i>Annals of Internal Medicine</i> , 1987 , 106, 777-8	8	7
5	Effects of endothelial cell injury on pulmonary vascular reactivity. <i>Chest</i> , 1985 , 88, 213S-216S	5.3	5
4	Fatal outcome following nifedipine for pulmonary hypertension. <i>Chest</i> , 1983 , 83, 708-9	5.3	25
3	The effect of oral hydralazine on the pulmonary hemodynamics of patients with pulmonary foreign body granulomatosis. <i>Chest</i> , 1982 , 82, 708-12	5.3	7
2	Transient pulmonary hypertension from the intravenous injection of crushed, suspended pentazocine tablets. <i>Chest</i> , 1981 , 80, 178-82	5.3	26

- 1 Gallium scans and serum angiotensin converting enzyme levels in talc granulomatosis and lymphocytic interstitial pneumonitis. *Southern Medical Journal*, **1980**, 73, 1663-7

0.6 7